Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 39

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 39
---
 events could interrupt the marketing and sales of products in our stores, including our private label products, severely damage
our brand reputation and public image, increase the cost of products in our stores, result in product recalls or litigation, and impede
our ability to deliver merchandise in sufficient quantities or quality to our stores, which could result in a material adverse effect
on our business, financial condition, results of operations and cash flows.

The
global nutraceutical market is highly competitive, with many brands offering products that are similar to Nugevia. Failure to differentiate
from competitors could limit market penetration and revenue potential.

The
global nutraceutical market, valued at $451.7 billion in 2023, is highly competitive, with established players like Nestlé Health
Science, Amway, and smaller niche brands vying for market share. Nugevia’s reliance on resveratrol, despite JOTROL™’s
enhanced bioavailability, faces skepticism due to past studies questioning resveratrol’s efficacy and may require additional clinical
data. Convincing consumers and healthcare professionals of Nugevia’s superior performance will require effective marketing. Failure
to differentiate from competitors offering similar longevity or beauty-from-within products could limit market penetration and revenue
potential.

The
Company is dependent on certain proprietary supply-chain vulnerabilities with operational and supply chain risks.

The
Company’s dependence on proprietary technology like JOTROL™ and partnerships, such as with Aquanova for NovaSOL® Astaxanthin,
introduces supply chain vulnerabilities. Disruptions in raw material availability, manufacturing delays, or quality control issues could
hinder production timelines and product consistency. Scaling up manufacturing to meet demand while maintaining pharmaceutical-grade standards
poses additional operational challenges. Any failure to deliver on the expected third quarter launch could erode consumer trust and investor
confidence.

If
there are intellectual property disputes relating to the JOTROL technology, it could threaten Nugevia’s market position

The
Company’s competitive edge hinges on its patented JOTROL™ technology. However, intellectual property disputes or challenges
to JOTROL patent validity could threaten Nugevia’s market position. Competitors may attempt to develop similar bioavailability-enhancing
technologies, which circumvent JOTROL’s patent. Furthermore, any adverse events linked to Nugevia’s ingredients, even if
rare, could result in product liability claims, damaging the brand’s reputation and financial stability.

33

ITEM
2. UNREGISTERED SALES OF E